再生元终止开发一款双靶点CAR-T;葛兰素史克BCMA ADC药物Blenrep获批上市

氨基观察
Oct 24, 2025

氨基观察-创新药组原创出品作者 | 黄凯细胞疗法前行不易。10月23日,再生元决定放弃从2seventy bio收购的双靶点CAR-T疗法bbT369,该药物正在处于早期研究的剂量递增阶段中,用于评估治疗复发/难治性B细胞非霍奇金淋巴瘤患者。原计划该研究将转入II期阶段,但再生元确认,公司已做出“战略性商业决定”,终止该研究。葛兰素史克ADC药物死而复生。10月23日,GSK宣布,美国FDA已批准...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10